The $1.2M Bottleneck: Why Big Pharma Is Betting on Automated IDMOs

The science behind advanced cell therapies has been proven, but commercial sustainability is currently hitting a massive wall: manufacturing. Traditional production is heavily dependent on manual intervention, which currently accounts for 45% to 50% of the total Cost of Goods Sold (COGS). With global clinical trials projected to increase by 102% in the coming years, the industry is facing an unprecedented capacity crunch. If your company relies on legacy CDMOs and manual, open-system processes, your pipeline is deeply vulnerable to severe supply chain bottlenecks, prohibitive facility costs, and devastating batch failures. Because the total cost of care for these complex therapies can easily exceed $1.2 million per patient, failing to modernize your manufacturing infrastructure doesn't just delay your clinical timelines'it actively destroys your commercial viability and prices patients out of life-saving care. You need to automate by design and rethink your manufacturing partnerships. In this session, industry leaders will unpack the disruptive macro-trend of the Integrated CDMO (IDMO) model, powered by AI and end-to-end robotics. You will discover why top-tier biopharma companies are actively deploying hundreds of millions of dollars into these next-generation automated platforms, so you can seamlessly transition to functionally closed systems, drastically reduce your COGS, and achieve true commercial scalability for your advanced therapies.